LOGIN
ID
PW
MemberShip
2025-09-14 12:01
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
Sanofi to dismiss 3 sales reps breaching compliance
by
An, Kyung-Jin
Jun 25, 2020 06:08am
Accused of false reporting client visits, three sales reps from Sanofi-Aventis Korea may be dismissed as recommended by the headquarters. The sales department seems to be stirred by the management and commented, ¡°The management has made a harsh decision disregarding the possibility of system error.¡± The sign of internal dispute is appa
Company
Hanmi's Gugu was released in Japan
by
Chon, Seung-Hyun
Jun 25, 2020 06:08am
Hanmi's erectile dysfunction treatment 'Gugu' was released in Japan as a treatment for prostate hyperplasia. According to Hanmi on the 23rd, Sandoz began to sell Gugu 2.5mg and 5mg from all over Japan on the 18th. The Japanese product name is ¡°Sandoz Tadalafil¡± (Tadalafil Tablets 2.5mg&8729;5mg ZA SANDOZ). Gugu is generic for Cialis,
Company
COVID-19 devastates outpatient prescription in April-May
by
Chon, Seung-Hyun
Jun 25, 2020 06:07am
Top pharmaceutical companies have been struggling with outpatient prescription sales for two consecutive months. The COVID-19 seems to have slowed down drug prescription for nine out of ten major pharmaceutical companies in last two months and impacted the overall prescription volume this year. On June 22, pharmaceutical market research firm
Company
COVID-19's budget is being delayed in the National Assembly
by
Nho, Byung Chul
Jun 24, 2020 06:14am
With the global spread of COVID-19, vaccines and treatments are urgently needed, and the government's promised support budget plan is not in progress. Unlike the fast and full support in developed countries, there is concern that the support may be delayed and the golden time to overcome COVID-19 may be missed. As of the 23rd, 15 dome
Company
Penmix in trial to evade patent on fat dissolving Belkyra
by
Nho, Byung Chul
Jun 24, 2020 06:14am
An injection CDMO Penmix (CEO Park Dongkyu) succeeded in evading patent on Allergan¡¯s under-chin fat reducing injection Belkyra (desoxycholic acid). On June 19, Intellectual Property Trial and Appeal Board validated the negative confirmation of patent scope on Belkyra¡¯s desoxycholic acid and other pharmaceutical substance based on the
Company
Patients with Ultracet don't get benefit for anticancer drug
by
Eo, Yun-Ho
Jun 23, 2020 06:21am
There have been cases that do not meet the intention of the original insurance benefit standard in the treatment of prostate cancer. Targeted anticancer drug options such as 'Zytiga (Abiraterone acetate)' and 'Xtandi (Enzalutamide)' currently exist in adult resistant castration resistant prostate cancer (mCRPC). Moreover, since last May, t
Company
Immunotherapies tap on SCLC treatment area for more options
by
Eo, Yun-Ho
Jun 23, 2020 06:21am
One after another, immunotherapies are tapping into the unexplored small cell lung cancer (SCLC) treatment area. According to the pharmaceutical industry sources on June 20, AstraZeneca¡¯s Imfinzi (duvalumab), following Tecentriq (atezolizumab) by Roche, has been indicated as a first-line treatment for SCLC by Korea¡¯s Ministry of Food
Company
Daewoong wins first patent dispute in Belkyra after 2 years
by
Kim, Jin-Gu
Jun 22, 2020 06:10am
Daewoong has passed the first gateway for the release of generic for Belkyra (Deoxycholic acid), which targets and eliminates fat cells under the chin. Daewoong won the patent dispute that has been leading for two years with Allergan. The IPT ( Intellectual Property Trial and Appeal Board) made a trial decision on the 19th at Daewoong P
Company
Big 5 DC pass HIV treating two-drug regimen Dovato
by
Eo, Yun-Ho
Jun 22, 2020 06:08am
General hospitals in Korea are reviewing the prescription of GlaxoSmithKline¡¯s (GSK) Dovato, a two-drug regimen indicated to treat HIV-1 infection. The pharmaceutical industry sources reported the drug committees (DC) at the Big Five general hospitals like Seoul National University Hospital and Severance Hospital have passed Dovato (dol
Company
Yuyu Pharma exports FDA-approved COVID-19 test kit
by
Lee, Seok-Jun
Jun 22, 2020 06:08am
In partnership with SD Biosensor, Yuyu Pharma is to export COVID-19 test kit. At SD Biosensor headquarters office in Suwon on June 17, two companies signed a supply deal on real time polymerase chain reaction (RT-PCR) test kit for COVID-19. SD Biosensor¡¯s COVID-19 test kit has received the U.S. Food and Drug Administration¡¯s (FD
<
331
332
333
334
335
336
337
338
339
340
>